TRANS GENIC INC. News Releases 2008

2009


Sep. 18	Launch of Anti Human COPZ1 Monoclonal Antibody
Sep. 11	Launch of AGEs Assay Kit
Aug. 31	Launch of Anti GPCR Monoclonal Antibodies
Jul. 27	Notice of Conclusion of Joint Research and Development Agreement with International Medical Center of Japan
Jul. 22	Launch of Anti GPCR Monoclonal Antibodies
Jun. 26	Notice of Revised Consolidated Earnings Forecast
Jun. 26	Kajitsudo is Included in the Scope of Consolidation
Jun. 24	Launch of Anti GPCR Monoclonal Antibodies
Jun. 19	TRANS GENIC Granted Japanese Patent for Antibody against Pancreatic Cancer Marker and its Diagnostic Application
May. 15	Notice of Change of Directors
May. 15	Notice of Partial Amendment to Articles of Incorporation
Apr. 23	Notice of Resignation of Director
Apr. 20	Notice of Capital and Business Tie-up with Kajitsudo
Apr. 20	TRANS GENIC Licenses Knockout Mouse to Takeda Pharmaceutical Company
Apr. 10	“GANP® Mouse Technology” has been Patented by European Patent Office
Apr. 09	Notice of Conclusion of Marketing Agreement with Transposagen Biopharmaceuticals, Inc.
Apr. 02	Notice of Change of CEO
Feb.26	"GANP® Mouse Technology” has been Patented by Australian Patent Office
Feb.09	Patent Application for Antibody against Bile Duct Cancer Marker and its Diagnostic Application
Jan.22	TRANS GENIC’s Subject was Selected for “Science and Technology Incubation Program in Advanced Regions” by Japan Science and Technology Agency
Jan.19	Notice of Conclusion of Joint Research Agreement with National Cancer Center